In halt­ing con­fir­ma­to­ry tri­al for On­copep­tides' ac­cel­er­at­ed ap­proval, FDA notes in­creased risk of death

The FDA on Wednes­day morn­ing alert­ed pa­tients and health­care pro­fes­sion­als that the con­fir­ma­to­ry tri­al for On­copep­tides’ mul­ti­ple myelo­ma drug Pepax­to (mel­pha­lan flufe­namide) has been halt­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER